5 Value Picks Amid AI-Driven Tech Sell-Off & U.S.-Iran Tensions

AI fears and U.S.-Iran tensions rattle markets. Value investors should consider buying stocks like HRMY, AGRO, SQM, ANGI and PHIN.

Zacks Investment Research • Feb 4, 2026

5 Low Price-to-Book Stocks That Are Worth Watching in February

Low P/B screen spotlights IVZ, HRMY, CNXC, PAX and GPN as undervalued picks with solid growth potential heading into 2026.

Zacks Investment Research • Feb 2, 2026

Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity

Sandip Kapadia sold 3,746 shares directly for a total transaction value of approximately $139,171 on Jan. 26, 2026. Kapadia had sold all of his shares in Harmony Biosciences earlier in January, but his stock options and restricted stock units vested, bringing him back into partial ownership of the company.

The Motley Fool • Feb 1, 2026

Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800

Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue from one of its top products.

The Motley Fool • Feb 1, 2026

Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800

Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue from one of its top products.

The Motley Fool • Feb 1, 2026

4 Value Stocks to Consider as Tech Volatility Weighs on Wall Street

Tech turmoil weighs on Wall Street, but CNXC, GPN, HRMY, and UHS stand out with low P/CF ratios and solid growth.

Zacks Investment Research • Jan 30, 2026

Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes"

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research • Jan 29, 2026

4 GARP Stocks With Attractive PEG Ratios and Strong Growth Outlooks

Four GARP stocks - including NEXA - pair discounted PEG ratios with strong growth potential, showing how value and growth can work together.

Zacks Investment Research • Jan 29, 2026

How Harmony Biosciences Can Prove Its Skeptics Wrong

Harmony Biosciences has thrived due to the success of its Wakix narcolepsy treatment. Harmony is looking to extend the life of the intellectual property behind Wakix through new versions of the compound pitolisant.

The Motley Fool • Jan 28, 2026

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?

Harmony's approved narcolepsy drug Wakix has been a huge financial success. Controversy and litigation surrounding Wakix have held back the stock.

The Motley Fool • Jan 27, 2026